Drug profile · INN
pitolisant hydrochloride
WAKIX
pitolisant hydrochloride (WAKIX) is a histamine h3 receptor inverse agonist. Associated with Harmony Biosciences Holdings. Route of administration: oral. Current US regulatory status: approved.
Drug details — pitolisant hydrochloride
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 3
- Programs
- 4
- Data quality
- 0.89
Quick answer
pitolisant hydrochloride (WAKIX) is a histamine h3 receptor inverse agonist. Associated with Harmony Biosciences Holdings. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Histamine H3 receptor inverse agonist
Primary target: Histamine H3 receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is pitolisant hydrochloride?
pitolisant hydrochloride (WAKIX) is a histamine h3 receptor inverse agonist. Associated with Harmony Biosciences Holdings. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for pitolisant hydrochloride?
WAKIX is a marketed brand name for pitolisant hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of pitolisant hydrochloride?
pitolisant hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.